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Background: Ebolaviruses induce lethal viral hemorrhagic fevers (VHFs) in humans and non-human primates, with
the exceptions of Reston virus (RESTV), which is not pathogenic for humans. In human VHF cases, extensive
analyses of the humoral immune responses in survivors and non-survivors have shown that the IgG responses to
nucleoprotein (NP) and other viral proteins are associated with asymptomatic and survival outcomes, and that the
neutralizing antibody responses targeting ebolaviruses glycoprotein (GP1,2) are the major indicator of protective
immunity. On the other hand, the immune responses in non-human primates, especially naturally infected ones,
have not yet been elucidated in detail, and the significance of the antibody responses against NP and GP1,2 in
RESTV-infected cynomolgus macaques is still unclear. In this study, we analyzed the humoral immune responses of
cynomolgus macaque by using serum specimens obtained from the RESTV epizootic in 1996 in the Philippines to
expand our knowledge on the immune responses in naturally RESTV-infected non-human primates.
Results: The antibody responses were analyzed using IgG-ELISA, an indirect immunofluorescent antibody assay
(IFA), and a pseudotyped VSV-based neutralizing (NT) assay. Antigen-capture (Ag)-ELISA was also performed to
detect viral antigens in the serum specimens. We found that the anti-GP1,2 responses, but not the anti-NP
responses, closely were correlated with the neutralization responses, as well as the clearance of viremia in the sera
of the RESTV-infected cynomolgus macaques. Additionally, by analyzing the cytokine/chemokine concentrations of
these serum specimens, we found high concentrations of proinflammatory cytokines/chemokines, such as IFNγ, IL8,
IL-12, and MIP1α, in the convalescent phase sera.
Conclusions: These results imply that both the antibody response to GP1,2 and the proinflammatory innate
responses play significant roles in the recovery from RESTV infection in cynomolgus macaques.
Keywords: Ebola, Ebolavirus, Reston virus, Reston ebolavirus, Filovirus, Zoonosis, Humoral immune response,
Cynomolgus macaque, Cytokine, Antibody* Correspondence: morikawa@nih.go.jp
1Special Pathogens Laboratory, Department of Virology 1, National Institute
of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011,
Japan
Full list of author information is available at the end of the article
© 2012 Taniguchi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Taniguchi et al. BMC Veterinary Research 2012, 8:189 Page 2 of 10
http://www.biomedcentral.com/1746-6148/8/189Background
The family Filoviridae includes three genera, Ebolavirus,
Marburgvirus, and Cuevavirus. The genus Ebolavirus cur-
rently has five members: Bundibugyo virus (BDBV), Ebola
virus (EBOV), Reston virus (RESTV), Sudan virus
(SUDV), and Taï Forest virus [1]. Filoviruses induce lethal
viral hemorrhagic fevers (VHFs) in both humans and non-
human primates, while RESTV infection in humans is
probably subclinical, yet it also causes highly lethal VHF
in macaques [2,3]. RESTV epizootics among cynomolgus
macaques emerged in 1989, 1990, 1992, and 1996. In all of
these epizootics, the cynomolgus macaques originated in a
single primate breeding facility in the Philippines [4]. Al-
though the natural reservoir of RESTV remains unknown,
RESTV was isolated from pigs in the Philippines, in
addition to porcine reproductive and respiratory syn-
drome virus (PRRSV) and porcine circovirus type-2 in
2008 [5]. Considering the social impact of ebolaviruses, it
is important to understand the endemic and epizootic sta-
tus of RESTV in the Philippines.
In this study, we investigated the antibody responses
of cynomolgus macaques that could be dead-end hosts
for RESTV. Using serum specimens collected from
cynomolgus macaques during a RESTV outbreak in the
Philippines in 1996, we attempted to elucidate the sig-
nificance of neutralizing antibodies to RESTV in viral
clearance. We have previously established an enzyme-
linked immunosorbent assay (ELISA) and an indirect
immunofluorescent antibody assay (IFA) specific for
RESTV nucleoprotein (NP) [6-8]. These assays are useful
tools for investigating the signs of RESTV infection in
cynomolgus macaques. In human cases, antibody
responses against ebolaviruses have been analyzed exten-
sively: IgG responses to NP and other structural proteins
(e.g., VP40 and VP35) have been shown to correlate with
asymptomatic and surviving cases, and neutralizing anti-
body responses targeting the ebolaviruses glycoprotein
(GP1,2) appear to be the major indicator of protective
immunity [9].
On the other hand, proinflammatory cytokines/che-
mokines are known to play a major role in the patho-
genesis of ebolaviruses infections in various species.
Previous studies have shown an uncontrolled secretion
of proinflammatory cytokines/chemokines to contribute
to a fatal outcome in EBOV-infected humans [10] and
cynomolgus macaques [11]. Strong proinflammatory
cytokine/chemokine responses are also observed in con-
valescent or asymptomatic cases [12,13]. In RESTV-
infected cynomolgus macaques, high viremia has been
shown to induce the secretion of proinflammatory cyto-
kines/chemokines [14]. However, there have so far only
been a limited number of studies on the impact of
proinflammatory cytokine/chemokine responses in the
convalescent phase of RESTV infection.In this study, we grouped the cynomolgus macaque
samples based on the presence of RESTV NP-antigen in
sera and analyzed the antibody reactions and cytokine/
chemokine inductions to evaluate the presence of neu-
tralizing antibody to RESTV. We found that the anti-
GP1,2 responses, but not the anti-NP responses, were
closely correlated with the neutralization antibody
responses, as well as the clearance of viremia, in the sera
of RESTV-infected cynomolgus macaques. Additionally,
a high concentration of proinflammatory cytokines/
chemokines was detected in the convalescent phase spe-
cimens. These data suggest that both the anti-GP1,2
responses and proinflammatory cytokines/chemokines
play significant roles in the recovery from RESTV infec-
tion in cynomolgus macaques.
Results
RESTV NP-and GP1,2-specific antibodies, neutralizing
antibody responses, and the viral antigens in the
cynomolgus macaque sera from the 1996 RESTV epizootic
Twenty-seven serum samples derived from cynomolgus
macaques that were either found already dead or had been
euthanized at the facility were available. The presence of
RESTV NP antigens was evaluated by antigen-capture
ELISA [15] or immunohistochemistry [3], while that of
anti-RESTV NP IgG was evaluated using IgG ELISA and
IFA methods [6-8]. RESTV NP antigens were detected in
the liver in # 2182, 2612, 2615, 2669, 2739, 2921, 2644 and
2728, while RESTV NP was detected by antigen capture
ELISA in the sera of #2182, 2612, 2408, 2615, 2669, 2739,
2921, 2721 and 2972. We therefore assumed that these
cynomolgus macaques had suffered from the acute
viremic phase of the disease. Seventeen of the 27 samples
(#2408, 2615, 2669, 2739, 2921, 2728, 2180, 2181, 2189,
2190, 2191, 2195, 2404, 2693, 2696, 2713 and 2194) were
positive for anti-NP IgG in IgG ELISA, while these sam-
ples all reacted in IFA. On the other hand, two samples
(#2644 and 2719) were only positive in IFA. We consid-
ered the samples as anti-NP IgG-positive when either
ELISA or IFA showed positive reaction. As a result, a total
of 19 samples had anti-NP IgG. Cynomolgus macaques
with anti-NP IgG consisted of NP antigen-positive (#2408,
2615, 2669, 2739, 2921, 2644 and 2728) and NP antigen-
negative groups (#2180, 2181, 2189, 2190, 2191, 2195,
2404, 2693, 2696 and 2713).
In order to examine whether the sera contained anti-
GP1,2 antibodies, we employed a GP1,2-specific ELISA
and IFA [16]. RESTV GP1,2ΔTM prepared by a baculo-
virus expression system and RESTV GP1,2-expressing
HeLa cells were used as antigens for GP1,2-specific
ELISA and IFA, respectively. Anti-RESTV GP1,2 IgG
were detected in 10 (#2180, 2181, 2189, 2190, 2191,
2195, 2404, 2693, 2696 and 2713) out of the 27 serum
samples according to ELISA (37%), whereas the
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Nine serum samples positive for GP1,2 antibodies in the
IgG-ELISA also showed positive reactions in the IFA,
while one serum sample (#2194) was only positive in the
IFA. Serum samples showing positive reactions in either
the GP1,2-specific IgG-ELISA or IFA were considered to
be anti-GP1,2 positive (11/27, 41%, Table 1). Interestingly,
the sera derived from cynomolgus macaques in the acute
viremic phase did not contain any detectable anti-GP1,2
IgG, although they often contained anti-NP IgG.
We next attempted to detect the neutralization (NT)
antibody response in the sera of RESTV-infected cyno-
molgus macaques. The VSV pseudotype RESTV GP1,2
(VSV-RESTV-GP1,2/GFP) was used for the NT assay
[17]. Twelve serum samples (12/27, 44%) neutralized theTable 1 Antibody responses and viremic status of Reston viru
Case ID Anti-NP IgG Anti-GP1,2 IgG
ELISA IFA ELISA IFA
2182 - <80 - <80
2612 - <80 - <80
2408 + 10240 - <80
2615 + 2560 - <80
2669 + 2560 - <80
2739 + 1280 - <80
2921 + 1280 - <80
2644 - 80 - <80
2728 + 1280 - <80
2721 - <80 - <80
2972 - <80 - <80
2180 + 1280 + 320
2181 + 80 + 80
2189 + 1280 + 320
2190 + 160 + 640
2191 + 640 + 320
2195 + 2560 + 640
2404 + 1280 + 160
2693 + 160 + <80
2696 + 2560 + 160
2713 + 5120 + 320
2719 - 80 - <80
832 - <80 - <80
888 - <80 - <80
1134 - <80 - <80
2636 - <80 - <80
2194 + 5120 - 80
No. of positive samples 17/27 19/27 10/27 10/27
19/27 (70%) 11/27 (41%)
*ND: not determined, **euthanized: monkeys were euthanized regardless of clinical
negative, NT+: neutralization antibody positive, NT-: neutralization antibody negativ
phase. The specimens with case IDs written in bold were considered in convalescenVSV-RESTV-GP1,2/GFP infection, with NT titers ran-
ging from 80 and 640 (#2721, 2972, 2180, 2181, 2189,
2190, 2191, 2195, 2404, 2693, 2696 and 2713) (Table 1).
The anti-GP1,2 IgG were not detectable in #2721 and
#2972 by IgG ELISA, while those samples both had a
neutralizing activity. These two specimens showed a
positive response for viral antigen in the Ag-capture
ELISA and were thus considered to be collected in an
early seroconversion phase.
All cynomolgus macaques at the facility were euthana-
tized regardless of clinical status and there was a possi-
bility that some of the cynomolgus macaques had
combined infection with simian hemorrhagic fever virus
(SHFV) in the animal facility [18]. Therefore, immune





- + + Ag + NT - euthanized
- + + Ag + NT - euthanized
- *ND + Ag + NT - #NR
- + + Ag + NT - euthanized
- + + Ag + NT - euthanized
- + + Ag + NT - euthanized
- + + Ag + NT - euthanized
- + ND Ag + NT - euthanized
- + ND Ag + NT - euthanized
80 + + Ag + NT + euthanized
160 + + Ag + NT + dead
80 - - Ag - NT + dead
320 - - Ag - NT + dead
320 - - Ag - NT + NR
640 - - Ag - NT + NR
320 - - Ag - NT + NR
320 - - Ag - NT + NR
160 - - Ag - NT + dead
320 - - Ag - NT + euthanized
320 - - Ag - NT + euthanized
160 - - Ag - NT + euthanized
- ND ND NR
- ND ND NR
- ND ND NR
- ND ND NR
- ND ND euthanized
- ND ND dead
12/27 (44%) 11/21 (52%)
manifestation. #NR: not recorded, Ag +: antigen positive, Ag -: antigen
e. The specimens with case IDs written in italics were considered in acute
t phase.
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“convalescent” or “non-convalescent” based only upon
serological findings.
It is noteworthy that, among the serum samples that
were positive for viral antigen and negative for the NT
antibody (Ag +, NT -), all nine serum samples were nega-
tive for anti-GP1,2 antibodies, whereas only two samples
were negative for anti-NP antibodies. On the other hand,
all of the ten serum samples that were negative for viral
antigen and positive for the NT antibody (Ag -, NT +)
were positive for both anti-GP1,2 and anti-NP antibodies.
This finding indicates that the anti-GP1,2 antibody may
therefore increase in cynomolgus macaques in the conva-
lescent phase, while anti-GP1,2 antibody is rarely detect-
able in the acute viremic phase of infection.
Multiplex assay for cytokines and chemokines in the
cynomolgus macaque sera
Ebola virus infection triggers the expression of several
proinflammatory cytokines/chemokines [11,19,20]. To
examine whether the convalescence from the RESTV in-
fection correlates with the circulating proinflammatory
cytokines/chemokines, eleven RESTV-infected cynomol-
gus macaque serum samples were subjected to a multi-
plex cytokine analysis. Since we do not know when the
infection occurred for each cynomolgus macaque, it is
still unclear whether the sera represented an early or late
stage of infection. We used seven convalescent phase
sera (Ag-, NT +: #2404, 2181, 2189, 2693, 2696, 2713,
2180), and four acute viremic phase sera (Ag +, NT -:
#2182, 2612, 2739, 2921). Among the 27 serum samples,
only these 11 serum samples were available for multiplex
assay. Since the sera were heat-inactivated at 56°C for
30 min prior to being subjected to the multiplex ana-
lysis, some cytokines, such as GM-CSF and IL-2, which
were previously shown to be elevated in some RESTV
infected cynomolgus macaques [14], could not be mea-
sured in the assay.
We found that concentrations of several proinflamma-
tory cytokines/chemokines (e.g., IFNγ, IL8, IL-12, IL-1ra,
and MIP1α) were significantly higher in convalescent
than in acute phase sera (Figure 1). This observation is
similar to the previous studies showing elevated concen-
trations of proinflammatory cytokines/chemokines in
the convalescent or asymptomatic human cases [12,13].
In contrast, the concentrations of the five cytokines/che-
mokines (e.g., IFNα, IP-10, MIP1β, IL-6, and TNFα) did
not differ significantly between the two groups (Figure 2).
Furthermore, the concentration of MCP-1, one of the
proinflammatory chemokines, was lower in the convales-
cent than in the non-convalescent sera (Figure 2). These
data indicated that IFN-γ, IL-8, IL-12, IL-1ra or MIP1α
might therefore be involved with the host immune
responses in the convalescent phase of RESTV infection.Discussion
We previously developed a RESTV NP-specific IgG-
ELISA and IFA that proved to be useful for the seroepi-
demiological studies of cynomolgus macaques during
the RESTV epizootic in the Philippines in 1996 [6-8].
The assays based on recombinant NP are sensitive for
the detection of RESTV-specific antibodies. On the
other hand, anti-GP1,2 antibodies are elicited in EBOV-
infected human cases and are believed to have protective
roles against lethal EBOV infection [21,22]. In the
present study, in order to gain insight into the IgG
responses during the recovery from infection with
RESTV, anti-NP, anti-GP1,2, and neutralizing antibodies
and the level of viremia in the serum specimens were
analyzed. The data presented herein showed that the
anti-GP1,2 response, rather than the anti-NP response,
was correlated with both the lack in viremia and the
neutralizing activities in the sera of RESTV-infected
cynomolgus macaques. There may be at least two possi-
bilities for the lack of anti-GP1,2 IgG in the acute phase
samples. It is known that soluble GP (sGP), which does
not contain membrane anchor, is secreted during ebola-
viruses infection, and it can absorb the anti-GP1,2 anti-
bodies [23]. The other possibility is that apoptosis of
lymphocytes is induced during RESTV infection and the
resulting host immune responses may thus be abrogated.
Although the precise mechanism of action is still un-
known, it is likely that no IgG responses to RESTV
GP1,2 are induced in the cynomolgus macaques during
the acute phase of infection.
Since the cynomolgus macaques at the facility where
the RESTV epizootic occurred were euthanized, sequen-
tial serum specimens from each cynomolgus macaque
were not available. It is also difficult to determine when
each cynomolgus macaque became infected with
RESTV. We found that three specimens that have anti-
GP antibodies were obtained from dead monkeys
(#2180, 2181 and 2194), however, it is difficult to con-
clude whether RESTV infection caused their death be-
cause of the possibility of succumbing to infection by
SHFV or some other agents. It is predicted that, among
the serum samples examined here, nine were acute
phase samples because they were positive in Ag-ELISA
or immunohistochemistry [3,15] (Table 1). On the other
hand, all but one (serum #2194) of the anti-GP1,2-
positive serum samples were Ag negative. Therefore,
these cynomolgus macaques were considered to be in
the convalescent phase of RESTV infection. In this re-
gard, the presence of the anti-GP1,2 antibody is thought
to be a useful indicator for convalescence in cynomolgus
macaques infected with RESTV.
Aberrant proinflammatory cytokines/chemokines are a sig-
nificant factor implicated in the disease progression of












































































































































Figure 1 Profiles of the serum cytokine and chemokine concentrations in Reston virus-infected cynomolgus macaques. The serum
concentrations of IFN-γ, IL-8, IL-12, MIP1α, and IL-1ra. The concentrations of these proinflammatory cytokines/chemokines (IFN-γ, IL-8, IL-12, MIP1α)
and the anti-inflammatory cytokine (IL-1ra) were significantly higher in convalescent (Ag - NT +) than in non-convalescent sera (Ag + NT -). Each
dot represents one sample, and dashes (-) represent the median values. * indicates p < 0.05, ** indicates p < 0.005 (Mann Whitney test). Broken
lines and the numbers written aside indicate the average concentrations of cytokine and chemokine in negative control cynomolgus macaques
(n = 13).
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balanced proinflammatory response is believed to be a crit-
ical factor for determining the disease outcome [25,26]. We
focused on the circulating inflammatory cytokines/chemo-
kines in RESTV-infected cynomolgus macaques and exam-
ined their relationship with convalescence. We thus found
the concentrations of several proinflammatory cytokines/
chemokines, such as IFNγ, IL8, IL-12, and MIP1α, to besignificantly higher in convalescent sera than in non-
convalescent sera. Gupta et al. (2012) recently demonstrated
that convalescent serum samples obtained from BDBV-
infected human cases include high concentrations of IL-1α,
IL1β, IL6, TNFα, and MCP-1 [13]. Although the exact pro-
files of proinflammatory cytokines/chemokines shown in our
study are different from those reported by Gupta et al., these










































































































































































Figure 2 Profiles of the serum cytokine and chemokine concentrations in Reston virus-infected cynomolgus macaques. The IFN-α, IP-10,
TNF-α, MIP1β, IL-6 and MCP-1 concentrations. The serum concentrations of these cytokines/chemokines (IFN-α, IP-10, TNF-α, MIP1β) did not differ
significantly between the convalescent cases (Ag - NT +) and the non-convalescent cases (Ag + NT -). The concentration of the anti-inflammatory
cytokine, MCP-1, was lower in convalescent than in non-convalescent cynomolgus macaques (Mann Whitney test). Each dot represents one
sample, and dashes (-) represent the median values. Broken lines and the numbers written aside indicate the average concentrations of cytokine
and chemokine in negative control cynomolgus macaques (n = 13).
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cies (cynomolgus macaques vs. humans), and differences
related to the disease phase when the samples were obtained.
It is possible that the upregulation of the proinflammatory
innate immune responses contributed to the recovery from
RESTV infection in cynomolgus macaques.
In rhesus monkeys experimentally infected with a lethal
dose of EBOV, anti-inflammatory cytokines, such as IL-13
and IL-1ra, are highly elevated in the acute phase [11]. Inhuman Ebola VHF patients, increased concentrations of
IL-10 and IL-1ra have been shown in fatal cases, thus sug-
gesting that the mixed anti-inflammatory response syn-
drome (MARS) contributes to the pathogenesis of the
hemorrhagic fever caused by ebolaviruses. Since all of the
cynomolgus macaques involved in the epizootic were
euthanized at the affected facility, the actual fate of the
cynomolgus macaques was not clear, and some might have
survived the infection. Our data obtained using the sera
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showed higher IL-1ra responses in the convalescent phase
than in the non-convalescent phase (Figure 1). There were
no significant differences in the concentration of IL-10 be-
tween the two groups (data not shown). This suggests
that, unlike other ebolaviruses infections, RESTV does not
induce MARS, which is characterized by an elevated in-
duction of IL1ra in the acute phase.
In conclusion, we have shown that the anti-GP1,2
responses, rather than the anti-NP responses, in cyno-
molgus macaques naturally infected with RESTV were
specifically detected in the convalescent stage of RESTV
infection. In addition, a high concentration of proinflam-
matory cytokines/chemokines was observed in the con-
valescent phase. Therefore, the anti-GP1,2 response and
the upregulation of the specific proinflammatory re-
sponse might be useful indicators of convalescence from
RESTV infection in cynomolgus macaques.
Conclusions
In this study, we analyzed the humoral responses in cyno-
molgus macaque serum samples collected during the 1996
Reston outbreak in the Philippines and demonstrated that
the anti-RESTV GP1,2 response and the proinflammatory
innate response play significant roles in the convalescence
from RESTV infection in cynomolgus macaques.
Methods
Sera
Twenty-seven cynomolgus macaque serum samples were
obtained from the cynomolgus macaque facility in the
Philippines where the 1996 RESTV epizootic occurred
[27]. The serum specimens in the affected facility were
collected under quarantine of the Philippines. Nineteen
of the 27 samples were previously subjected to an anti-
gen capture ELISA. Nine of the samples were found to
be RESTV antigen-positive, and the remaining 10 were
considered to be antigen-negative [15]. The serum speci-
mens were treated at 56°C for 30 minutes and virus in
the cynomolgus macaque serum samples were inacti-
vated. As negative controls for the IgG-ELISA and IFA,
we used serum samples from 102 cynomolgus macaques
collected at the Tsukuba Primate Research Center
(TPRC) in Japan. As positive controls for the IgG-ELISA
and IFA, two rabbits were immunized four times with
the histidine-tagged ectodomain of the RESTV glycopro-
tein (GP1,2) (RESTV GP1,2ΔTM). The histidine-tagged
RESTV GP1,2ΔTM of a 1996 RESTV [28] was prepared
and purified as described below. The sera were collected
from the rabbits, inactivated, and stored at 4°C until use.
The experiments with animals were performed in ac-
cordance with the Animal Experimentation Guidelines
of the National Institute of Infectious Diseases. The
protocol was approved by the Institutional Animal Careand Use Committee of the institute (Permit number:
990163 and 109075).
Expression and purification of the recombinant RESTV
GP1,2 ectodomain
A recombinant baculovirus that expresses RESTV
GP1,2ΔTM was used to prepare recombinant RESTV
GP1,2 for the IgG-ELISA [16]. Briefly, a recombinant
baculovirus carrying the ectodomain of RESTV GP1,2
(DDBJ accession no. AB050936) with histidine-tag
sequences at its 3’-terminus was infected into Tn5 cells
at a multiplicity of infection (moi) of 1. The cells were
collected, washed with PBS, and then lysed in PBS
containing 1% Nonidet P40 (NP-40) on ice for 15 min.
After being centrifuged, the recombinant RESTV
GP1,2ΔTM was purified with Ni
2+-agarose beads (QIA-
GEN, Hilden, Germany) and His Bind Kits (Novagen,
Darmstadt, Germany). The purified recombinant RESTV
GP1,2ΔTM was used for the IgG-ELISA specific for
RESTV GP1,2. Lysates of Tn5 cells infected with baculo-
virus with a deleted polyhedrin gene, Ac-ΔP, were simi-
larly processed and then used as negative control
antigen in the IgG-ELISA described below.
RESTV GP1,2-specific IgG-ELISA
Ninety-six well plates were coated with the RESTV
GP1,2ΔTM or with negative control antigen in 100 μl of
PBS and incubated overnight at 4°C. The plates were
washed three times with PBS containing 0.05% Tween
20 (PBS-T), and then 200 μl of PBS-T containing 5%
skim milk (SKIM-PBS-T) was added to each well and
incubated for 2 hr at 37°C. The cynomolgus macaque
sera were diluted at 1:100, 1:400, 1:1,600, and 1:6,400 in
SKIM-PBS-T, and the hyperimmune rabbit sera were
four-fold serially diluted from 1:1,000 to 1:64,000 in
SKIM-PBS-T. One hundred microliters of each serum
dilution was added to the antigen-coated wells and incu-
bated for 1 hr at 37°C. After they were washed three
times with PBS-T, the wells were further reacted with
either HRP-conjugated goat anti-human IgG (H + L)
(Lot:60504974, ZyMED) or HRP-conjugated goat anti-
rabbit IgG (H + L) (Lot:398581A, ZyMED) at a dilution
of 1:1,000 in SKIM-PBS-T. After being washed three
times again with PBS-T, the ABTS substrate (Roche
Diagnostics) was added to the wells. Then, the plates
were incubated for 30 minutes at 37°C, and the OD
values of the wells at 405 nm were measured. Adjusted
OD values were calculated by subtracting the OD value
of the wells coated with the negative control antigen
from that of the wells coated with RESTV GP1,2ΔTM.
RESTV NP-specific IgG-ELISA
The NP-specific IgG-ELISA, which is similar to the
GP1,2-specific ELISA except for the purified recombinant
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been previously reported [6,16].
ELISA index and determination of the cut-off value for
the IgG-ELISA
The sum of the OD values of serum dilutions at 1:100,
1:400, 1:1,600, and 1:6,400 for each specimen was calculated
and designated as an “ELISA index” in the IgG-ELISA. The
mean plus three standard deviations (SD) of the ELISA in-
dices for the IgG-ELISAs was calculated using serum sam-
ples from uninfected TPRC cynomolgus macaques and was
used as the cut-off value for the IgG-ELISAs.
Indirect immunofluorescent antibody assay (IFA) specific
for RESTV NP and GP1,2
The IFA specific for RESTV NP was reported previously
[8]. In the present study, a RESTV GP1,2-specific IFA
was established using stably RESTV GP1,2-expressing
HeLa cells. HeLa cell line was purchased from the
American Type Culture Collection and used. The
RESTV GP1,2 cDNA of a 1996 RESTV was subcloned
into a mammalian expression plasmid, pKS336, to gen-
erate pKS336-RESTV-GP1,2. The HeLa cells expressing
RESTV GP1,2 were selected in a medium containing
2 μg/ml of blasticidin-S-hydrochloride (Sigma, St. Lois,
MO) after transfection with pKS336-RESTV-GP1,2 using
the FuGENE HD Transfection Reagent (Roche Diagnos-
tics, Germany). The cells were trypsinized, washed with
PBS, and mixed with normal HeLa cells, and were then
spotted on 14 well Teflon-coated glass slides, air dried,
and fixed with acetone at room temperature for 5 min.
The slides were stored at -80°C until use.
The slides were thawed and dried just before use. The
serum specimens were 2-fold serially diluted in PBS, and
a 20 μl aliquot of each dilution was applied to the wells
of the antigen slides and incubated at 37°C for 1 hr in a
humidified chamber. Then the antigen slides were
washed with PBS and reacted with 20 μl per well of
FITC-conjugated goat anti-human IgG (H + L) (ZyMax
lot: 415460A, Invitrogen, CA, U.S.A.) for cynomolgus
macaque sera and FITC-conjugated goat anti-rabbit IgG
(H + L) (ZyMax lot: 402686A, Invitrogen, CA, U.S.A.)
for rabbit hyperimmune sera at a dilution of 1:100. After
incubation at 37°C for 1 hr, the slides were washed with
PBS and covered with micro cover glasses. The slides
were examined for the staining pattern under a fluores-
cent microscope. The antibody titer in the IFA was
determined as the reciprocal of the highest dilution
showing positive staining.
RESTV neutralization (NT) assay using VSV-RESTV-GP1,2/
GFP
The VSV pseudotype bearing RESTV GP1,2, VSV-RESTV-
GP1,2/GFP was generated essentially according to themethod described for the VSV pseudotype bearing SARS-
CoV S protein [29], except that pKS336-RESTV-GP1,2 was
used in the present study [17]. Briefly, 293 T cells were
prepared in 24 well plates at 20-30% confluency. The cells
were transfected with pKS336-RESTV-GP1,2 using
FuGENE HD. The cells were then cultured for 24 hr and
inoculated with VSV ΔG*/GFP pseudotyped with the
VSV-G protein at a moi of 5, adsorbed for 1 hr at 37°C,
and then washed with DMEM-5% FCS and cultured for
24 hr. The culture supernatants were collected and centri-
fuged at 1,000 rpm to remove cell debris. Thereafter, the
supernatants were stored at -80°C as VSV-RESTV-GP1,2/
GFP. The infectivity titer of VSV-RESTV-GP1,2/GFP, har-
boring the VSV ΔG*/GFP genome, was determined by
counting the number of GFP-positive cells under a fluor-
escent microscope upon infection into Vero E6 cells, as
described previously. Briefly, VSV-RESTV-GP1,2/GFP was
3.2 (0.5 log10)-fold serially diluted with DMEM-5% FCS
and then inoculated to Vero E6 cells seeded in 96 well cul-
ture plates. The cells were incubated at 37°C in a CO2 in-
cubator for 24 hr. Then, GFP-positive cells were detected
and counted under a fluorescent microscope (BZ-9000;
KEYENCE, Osaka, Japan), and the infectious units (IU) of
the pseudotyped VSV were calculated.
The serum samples were serially diluted in DMEM-5%
FCS, and a 50 μl aliquot of each dilution was mixed with
the same volume of DMEM-5% FCS containing
1,000 IU of VSV-RESTV-GP1,2/GFP and incubated for
1 hr at 37°C. The mixture was inoculated into Vero E6
cells and incubated for 24 hr. The number of GFP-
positive infected cells was counted, and serum dilutions
with 50% neutralization (NT50) were identified.
Multiplex assay for cytokines and chemokines in the
cynomolgus macaque sera
Eleven RESTV-infected cynomolgus macaque serum
samples were inactivated at 56°C for 30 min, diluted
1:10 in the assay diluent supplied with the Human Cyto-
kine 25-Plex antibody bead kit (Invitrogen, CA), and
were subjected to a multiplex cytokine analysis using a
Luminex 100 instrument (Luminex Co., Austin, TX)
according to the manufacturer’s instructions. This
Human Cytokine 25-Plex antibody bead kit was previ-
ously used to cynomolgus macaque sera and the cross-
reactivity was confirmed [30]. As negative controls, we
used sera from 13 cynomolgus macaques bred at the
TPRC and investigated the cytokine concentrations of
these serum samples.
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